Novel thiazolyl-pyrimidine derivatives as potential anticancer agents: Synthesis, biological evaluation, and molecular docking studies

We synthesized and spectroscopically confirmed a series of 1,3-thiazolyl-pyrimidine derivatives to investigate their potential role in cancer therapy. These were created by reacting 2-(1-(6-methyl-2-oxo-4-phenyl- 1,2,3,4-tetrahydropyrimidin-5-yl)ethylidene)hydrazine-1-carbothioamide with hydrazonoyl...

Full description

Saved in:
Bibliographic Details
Main Authors: Tariq Z. Abolibda, Abdel-Aziz A.A. El-Sayed, Basant Farag, Magdi E.A. Zaki, Abdulwahed Alrehaily, Hossein M. Elbadawy, Ahmad A. Al-Shahri, Saleh R. Alsenani, Sobhi M. Gomha
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Results in Chemistry
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2211715624007045
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We synthesized and spectroscopically confirmed a series of 1,3-thiazolyl-pyrimidine derivatives to investigate their potential role in cancer therapy. These were created by reacting 2-(1-(6-methyl-2-oxo-4-phenyl- 1,2,3,4-tetrahydropyrimidin-5-yl)ethylidene)hydrazine-1-carbothioamide with hydrazonoyl halides and α-halo compounds, with structures confirmed by spectroscopy. The growth-inhibitory potential of these compounds against HepG2 liver cancer cells was assessed using the MTT assay. Five compounds, namely 8a, 10, 12a, 12b, and 14, exhibited promising anticancer activity with IC50 values of 5.02 ± 1.83, 4.04 ± 1.37, 3.81 ± 1.96, 2.39 ± 0.75, and 3.27 ± 1.13 μM, respectively, all of which were more effective than doxorubicin (IC50 = 6.18 ± 0.29 μM). Molecular docking analyses were conducted to investigate the probable binding conformations of the most potent anticancer agents. The docking studies were in good agreement with the in vitro biological results, revealing that compounds 12b, 14, 12a, 10, and 8a demonstrated strong molecular interactions with protein CK2 α. The compounds may serve as adjuvants in cancer treatment. In silico ADMET studies revealed that the synthesized compounds exhibit favorable oral bioavailability profiles.
ISSN:2211-7156